Abstract: This invention discloses a method for the preparation of 2?-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: This invention discloses a method for the preparation of 2′-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: This invention discloses a method for the preparation of 2′-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: This invention discloses a method for the preparation of 2′-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: This invention discloses a method for the preparation of 2′-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: This invention discloses a method for the preparation of 2'-modified nucleosides, using a palladium catalyst and an alkene functionalized with a heteroatom. Included in the invention are the novel pyrimidines and purines that can be prepared according to the method of the invention and oligonucleotides containing said modified pyrimidines and purines.

Abstract: A process for separating non-oxidizable compounds from a mixture containing at least one oxidizable compound. The mixture is contacted with ozone to oxidize oxidizable compounds to form oxidized compounds which are then converted to water-soluble hydrazones, followed by separation of the hydrazones from the mixture using precipitation, liquid/liquid extraction, chromatography, etc.

Abstract: A process for the conversion of glycoside substituted taxanes to taxol and related compounds that can serve as precursors to taxol. The process includes the oxidation of glycoside substituted taxanes to convert the glycoside to the hydroxyl group. The oxidation can occur in the presence of an acid or followed by treatment with acid. Application of the process to 7-xylosyl taxol ("XT") yields taxol; application to other glycoside substituted taxanes forms compounds that can serve as precursors for taxol. The process includes the formation of certain new taxol related intermediate compounds having a hemialdal at the C-7 site on the taxane ring, which hemialdal can then be converted to taxol or taxol precursors. Since glycoside substituted taxanes are isolated with taxol from naturally occurring biomass, their conversion to taxol using the process of the present invention significantly improves the total yield of taxol from natural sources.

Abstract: A process for separating non-oxidizable compounds from a mixture containing at least one oxidizable compound. The mixture is contacted with ozone to oxidize oxidizable compounds to form oxidized compounds which are then converted to water-soluble hydrazones, followed by separation of the hydrazones from the mixture using precipitation, liquid/liquid extraction, chromatography, etc.

Abstract: The invention relates to pharmaceutical compositions comprising an effective cytotoxic amount of: ##STR1## Wherein R represents Ac or H; R' represents: ##STR2## OH; and R" represents: ##STR3## these new compounds demonstrate surprising tubulin binding activity and cytotoxicity.

Abstract: Antineoplastic taxol derivatives are derived by selective oxidation of the alkene portion of the side chain of cephalomannine. The derivative displays high activity in promoting assembly of microtubulin and also displays cytotoxic activity against malignant cells.

Abstract: A process for oxidizing cephalomannine and related taxanes in the presence of taxol is described. The process involves the use of ozone which is able to oxidize cephalomannine and easily oxidizable taxanes while leaving taxol essentially unchanged. Taxol can then be separated from the oxidized cephalomannine and other oxidized taxanes using conventional procedures. A process for oxidizing taxanes is also provided.